Comprehensive Novel Variant Discovery in Hereditary Cardiology and Neurology Research Using Next-Generation Sequencing, New Webinar Hosted by Xtalks

Press Release ( - TORONTO - Aug 23, 2018 - Join this live webinar on Sept. 11, 2018, to learn about how next-generation sequencing and Roche’s SeqCap EZ Cardiology and Neurology Panels enable researchers to discover novel variants in genes that are most commonly associated with hereditary cardiac and nervous system disorders, respectively.

Using guidance from peer-reviewed publications and Roche Sequencing Solutions’ scientific expertise, a suite of three SeqCap EZ Cardiology Panels and a suite of six SeqCap EZ Neurology Panels were developed. These panels were subsequently optimized for use with the HyperCap Workflow, which integrates KAPA library preparation and SeqCap EZ target enrichment products in a single streamlined workflow.

Some of the features of the panel include expert-driven gene content, sufficient breadth for variant discovery in various cardiological and neurological research applications, increased sequencing efficiency, improved uniformity to enable more even target coverage and a complete sample prep solution.

The suite of SeqCap EZ Cardiology Panels for research includes:

  • A cardiomyopathy panel which targets 76 genes associated with cardiomyopathies (primary target size: 372 kb)
  • A channelopathies and arrhythmias panel which targets 54 genes associated with channelopathies and arrhythmias (primary target size: 203 kb)
  • A sudden cardiac death panel which targets 140 genes associated with cardiomyopathies, channelopathies/arrhythmias and sudden cardiac arrest (primary target size: 610 kb)

The suite of SeqCap EZ Neurology Panels for research includes:

  • An epilepsy panel which targets 168 genes associated with epilepsy (primary target size: 440 kb)
  • A movement disorders panel enriches 209 genes associated with movement-related disorders (primary target size: 540 kb)
  • A neurodegeneration panel which targets 98 genes associated with neurodegenerative disorders (primary target size: 239 kb)
  • A neurodevelopment panel which targets 181 genes associated with neurodevelopmental disorders (primary target size: 557 kb)
  • A neuromuscular panel targets 144 genes associated with neuromuscular disorders (primary target size: 561 kb)
  • A neuropathy panel which targets 93 genes associated with neuropathological disorders (primary target size: 259 kb)

Research use of these SeqCap EZ Cardiology and SeqCap EZ Neurology panels may enable future discovery of novel disease-causing genetic variants.

During the interactive webinar, Dr. Todd Richmond will provide insights on the development of Roche’s newest designs in the areas of hereditary cardiology and neurology research.

For more information about this complimentary event, visit: Comprehensive Novel Variant Discovery in Hereditary Cardiology and Neurology Research using Next-Generation Sequencing.

For Research Use Only. Not for use in diagnostic procedure.
HYPERCAP, KAPA and SEQCAP are trademarks for Roche.


Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks, visit

For information about hosting a webinar, visit


Nima Rajan
Tel: +1 (416) 977-6555 ext 352

Source : Xtalks
Business Info :

You may also like this  


Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Or Signup using Email

Already have an account ? Login

Reset Password

Already have an account ? Login


If you have any concerns regarding this press release, please contact the Author / Media Contact / Business of this press release. ePRNews is not resposible for the accuracy of the news posted and do not endorse, support any product/ services/ business mentioned and hereby disclaims any content contained in this press release.